Standard BioTools to Sell Mass Cytometry Business to Multiplex Bio; Deal Expected to Close by End of 2026

Mass Cytometry Sale Details and Strategic Rationale

Standard BioTools disclosed that it has explored multiple opportunities for its Mass Cytometry business and determined that Multiplex Bio, led by advanced imaging industry veterans, represents the best home for the company's team, technology, and customers. The announcement indicates that Multiplex Bio's leadership team brings significant experience in spatial biology commercialization, imaging platform development, and life sciences operations. This assessment suggests Standard BioTools conducted a thorough evaluation process before selecting the buyer for this business unit.

The disclosure emphasizes that the sale is not effective immediately and remains subject to customary closing conditions. Standard BioTools committed to maintaining full continuity of business operations during the transition, including ongoing commercialization of CyTOF, Hyperion, and next-generation multiplex product lines. The company stated its intention to preserve all customer relationships, retain the majority of the existing team, and honor existing service and maintenance commitments. This focus on continuity suggests Standard BioTools is prioritizing stability for customers and employees during the transition period.

Multiplex Bio's Leadership and Vision for the Business

Multiplex Bio's leadership team includes Chief Executive Officer Michael Johnson, Chief Technology Officer Tom Villani, and Chief Operating Officer Charles Coffman. According to the announcement, Johnson is a co-founder of Visikol who pioneered commercialization of spatial biology tools including 3D microscopy and multiplex tissue imaging. Villani, also a Visikol co-founder, brings experience in advanced bioimaging and assay development. Coffman previously served as Chief of Staff and VP of Finance at HealthTrackRx, a molecular diagnostics company, and held finance and strategy roles at StageBio, a preclinical research services provider.

Multiplex Bio's stated vision is to become the number one leader in proteomic detection and imaging, positioning itself such that researchers conducting greater-than-10-plex imaging would have no reason to choose a competing platform. The company emphasizes its private, founder-owned structure enables faster decision-making than public competitors. This strategic positioning suggests Multiplex Bio intends to differentiate itself through operational agility and technical excellence in the multiplex imaging market.

Multiplex Bio's Planned Strategic Initiatives

The announcement outlines four primary strategic initiatives Multiplex Bio intends to execute under its leadership. First, the company plans to address the form factor challenges of mass cytometry by restarting the Theia product and becoming a competitive player in the 10-plus plex imaging segment. This initiative acknowledges that while mass cytometry offers strong detection capabilities, current systems are expensive, installation-intensive, and not benchtop-compatible. Fixing this form factor constraint represents a significant strategic priority for Multiplex Bio.

Second, Multiplex Bio plans to substantially expand service offerings, recognizing that 99 percent of spatial proteomics researchers will never purchase a device. The company intends to provide end-to-end services to all customers, addressing a substantial market segment underserved by traditional device-centric business models. Third, Multiplex Bio plans to develop comprehensive end-to-end software solutions that address current adoption barriers related to data analysis. The company recognizes that customers seek insights and actionable findings, not merely images, and aims to deliver integrated imaging-to-analysis platforms. Fourth, Multiplex Bio intends to modernize its marketing approach, shifting from technology-oriented messaging to solution-oriented positioning.

Employee Transition and Operational Continuity

The disclosure states that employee transition plans are a top priority and that Multiplex Bio and Standard BioTools are actively working through these arrangements. The announcement specifies that no changes to employment or organizational structure will take effect immediately. Instead, human resources will notify team members individually about transition plans as decisions are finalized. This phased approach suggests the parties intend to minimize disruption and provide clarity to affected employees before implementation.

Standard BioTools committed to providing transparency and regular updates regarding employment decisions and transition arrangements as they are made. This commitment reflects a recognition that employee retention and stability are critical to successful business continuity during the sale process. The disclosure also notes that a three-month transition period is planned post-closing, providing structured time for operational handoff and integration.

Timing, Approvals, and Transaction Conditions

The sale is expected to close by the end of 2026, substantially concurrent with the closing of Standard BioTools' Treeline transaction. The transaction remains subject to Standard BioTools obtaining approval from its shareholders. This timing linkage to the Treeline transaction suggests that both transactions are strategically coordinated components of Standard BioTools' broader corporate restructuring. The simultaneous closing of both transactions may create operational efficiencies and provide clarity to investors regarding the company's strategic direction.

The disclosure identifies several conditions and risks that could affect completion of the transaction. Standard BioTools must obtain shareholder approval, the various conditions to consummation must be satisfied or waived, and certain key events or circumstances could give rise to termination of the sale agreement. The announcement indicates that Standard BioTools is preparing preliminary proxy materials in connection with the shareholder vote on the Mass Cytometry business disposition.

Integration with Treeline Transaction and Broader Strategic Context

The Mass Cytometry sale is structured to close substantially concurrent with Standard BioTools' previously announced Treeline transaction. This timing synchronization indicates that Standard BioTools is executing a comprehensive strategic restructuring involving the disposition of multiple business units. The disclosure notes that both transactions require shareholder approval, suggesting investors will have the opportunity to vote on both initiatives in connection with the proxy solicitation process.

The filing references that Standard BioTools filed a Form S-4 registration statement on July 20, 2026, in connection with the Treeline transaction, which included preliminary proxy and prospectus materials. In connection with the Mass Cytometry disposition, Standard BioTools stated it will file a preliminary proxy statement with the Securities and Exchange Commission. This regulatory framework provides investors with detailed disclosure documents before voting on either transaction.

Risks and Uncertainties Related to Transaction Completion

The announcement identifies multiple risks and uncertainties that could prevent timely completion or completion of the Mass Cytometry sale. These risks include the possibility that the sale may not be completed in a timely manner or at all, failure to obtain requisite shareholder approval, conditions to consummation not being satisfied or waived, and termination events under the sale agreement. Additionally, the disclosure identifies risks related to Standard BioTools' ability to maintain the Mass Cytometry business as a standalone operation during the pre-closing period.

The announcement also identifies risks specific to the Treeline transaction that could affect both transactions, including risks that the Treeline transaction may not close timely or at all, shareholder approval may not be obtained, competing offers may be made, termination events could occur, and Standard BioTools could be required to pay termination fees. Stockholder litigation risks related to either transaction are identified as potential sources of significant defense costs and liabilities. Additional risks involve management distraction from ongoing operations and potential loss of key personnel.

Forward-Looking Statements and Regulatory Disclosures

The announcement contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding the disposition of the Mass Cytometry business, expected closing timing, the Treeline transaction, and future business operations. The company cautions that forward-looking statements are subject to risks, uncertainties, and assumptions, and that actual results may differ materially from expressed or implied expectations. Standard BioTools directs investors to its Risk Factors disclosures in its most recent Annual Report on Form 10-K filed March 16, 2026, its most recent Quarterly Report on Form 10-Q, and other regulatory filings.

The disclosure specifies that forward-looking statements speak only as of the date of the announcement, July 28, 2026, and that Standard BioTools does not assume an obligation to update forward-looking statements except as required by law. This standard cautionary language reflects the company's acknowledgment that circumstances and plans may change, and that investors should not rely on statements made on this date as reflections of future intentions or expectations.

Shareholder Communication and Information Access

The announcement indicates that the Mass Cytometry sale may be deemed solicitation material in respect to Standard BioTools' shareholder vote. Standard BioTools has committed to filing a preliminary proxy statement with the Securities and Exchange Commission in connection with the shareholder vote on the Mass Cytometry disposition. These documents will provide detailed disclosure regarding the transaction, including financial information, risk factors, and management recommendations.

Investors are directed to these proxy statements and prospectuses for complete disclosure regarding the transactions. The announcement notes that the current communication is not a substitute for these official disclosure documents and that investors should review all available regulatory filings for complete information before making voting decisions or investment determinations. The disclosure framework ensures shareholders have access to comprehensive information before voting on the Mass Cytometry sale.